# Toripalimab Combined With Radiotherapy in the Treatment of Oligometastatic Nasopharyngeal Carcinoma

> **NCT05147844** · PHASE2 · RECRUITING · sponsor: **Xinqiao Hospital of Chongqing** · enrollment: 40 (estimated)

## Conditions studied

- Nasopharyngeal Carcinoma

## Interventions

- **DRUG:** Toripalimab

## Key facts

- **NCT ID:** NCT05147844
- **Lead sponsor:** Xinqiao Hospital of Chongqing
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-03-01
- **Primary completion:** 2025-12-31
- **Final completion:** 2026-03-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-07-14

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05147844

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05147844, "Toripalimab Combined With Radiotherapy in the Treatment of Oligometastatic Nasopharyngeal Carcinoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05147844. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*